Status

Current conditions ICD-9-CM:
2003
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
2010
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
2012
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
375.15 TEAR FILM INSUFFICIENCY,UNSPECIFIED
367.89 OTHER DISORDERS OF REFRACTION AND ACCOMMODATION
377.61 ASSOCIATED WITH NEOPLASMS
729.1 MYALGIA AND MYOSITIS, UNSPECIFIED
719.39 PALINDROMIC RHEUMATISM,MULTIPLE SITES
680.0 CARBUNCLE AND FURUNCLE, FACE
378.41 ESOPHORIA
311 DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED
523.8 OTHER PERIODONTAL DISEASES(PERIODONTAL POCKET,GINGIVAL POLYP)
681.02 ONYCHIA AND PARONYCHIA OF FINGER
2013
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
704.8 OTHER DISEASES OF HAIR AND HAIR FOLLICLES
706.1 OTHER ACNE
444.22 ARTERIAL EMBOLISM AND THROMBOSIS OF LOWER EXTREMITY
375.15 TEAR FILM INSUFFICIENCY,UNSPECIFIED
367.89 OTHER DISORDERS OF REFRACTION AND ACCOMMODATION
377.61 ASSOCIATED WITH NEOPLASMS
378.41 ESOPHORIA
728.85 (728.850) SPASM OF MUSCLE
353.4 LUMBOSACRAL ROOT LESIONS,NOT ELSEWHERE CLASSIFIED
780.52 (780.520) OTHER INSOMNIA
788.43 NOCTURIA
2014
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
374.05 TRICHIASIS WITHOUT ENTROPION
372.72 CONJUNCTIVAL HEMORRHAGE
375.15 TEAR FILM INSUFFICIENCY,UNSPECIFIED
367.89 OTHER DISORDERS OF REFRACTION AND ACCOMMODATION
377.61 ASSOCIATED WITH NEOPLASMS
378.41 ESOPHORIA
2015
225.0 BENIGN NEOPLASM OF BRAIN
345.90 UNSPECIFIED EPILEPSY WITHOUT MENTION OF INTRACTABLE EPILEPSY
705.83 HIDRADENITIS
698.8 OTHER PRURITIC CONDITIONS
686.9 UNSPECIFIED LOCAL INFECTIONS OF SKIN AND SUBCUTANEOUS TISSUE
686.09 OTHER PYODERMA
272.0 PURE HYPERCHOLESTEROLAEMIA (FAMILIAL HYPERCHOLESTESTEROLEMIA)
729.1 MYALGIA AND MYOSITIS, UNSPECIFIED
719.39 PALINDROMIC RHEUMATISM,MULTIPLE SITES
377.61 ASSOCIATED WITH NEOPLASMS
311 DEPRESSIVE DISORDER, NOT ELSEWHERE CLASSIFIED
307.48 REPETITIVE INTRUSIONS OF SLEEP
705.81 DYSHIDROSIS
372.72 CONJUNCTIVAL HEMORRHAGE
680.2 CARBUNCLE AND FURUNCLE, TRUNK
523.3 ACUTE PERIODONTITIS(ACUTE PERICORONITIS)
Current conditions ICD-10-CM:
2016

E780 Pure hypercholesterolemia
G40.909 Epilepsy, unspecified, not intractable, without status epilepticus
L301 Dyshidrosis [pompholyx]
F32.9 Major depressive disorder, single episode, unspecified
D33.2 Benign neoplasm of brain, unspecified
H04.123 Dry eye syndrome of bilateral lacrimal glands
H47.529 Disorders of visual pathways in (due to) neoplasm, unspecified side
H02.052 Trichiasis without entropian right lower eyelid
H11.31 Conjunctival hemorrhage, right eye
H52.6 Other disorders of refraction
H50.51 Esophoria
H02.055 Trichiasis without entropian left lower eyelid
H47.099 Other disorders of optic nerve, not elsewhere classified, unspecified eye
F51.8 Other sleep disorders not due to a substance or known physiological condition
G40.901 Epilepsy, unspecified, not intractable, with status epilepticus
L0881 Pyoderma vegetans
B009 Herpesviral infection, unspecified
J069 Acute upper respiratory infection, unspecified
M79.1 Myalgia
M12.39 Palindromic rheumatism, multiple sites

Current treatment centers:
GP/ The department of Neurosurgical emergency & Critical Care of Chang Gung Memorial Hospital Linkou Branch/ TCM oncology of China Medical University Hospital Cancer Center/ and Taichung Hospital, Ministry of Health and Welfare

Contents of reference sources:
MIMS- Search drug information/ interaction/ images & medical diagnosis.
Complementary and Alternative Healing University- Dictionary of Chinese Herbs. http://alternativehealing.org
Database 醫砭‧沈藥子 http://yibian.hopto.org
Traditional Chinese Medicine (TCM) Wiki http://www.tcmwiki.com/

Monday, April 4, 2011

GENIQUIN FILM COATED TABLETS 200MG (HYDROXYCHLOROQUINE SULFATE)

藥品名稱(中文): 〝健亞〞殲瘧膜衣錠200公絲(硫酸羥氯奎寧)
藥品名稱(英文): GENIQUIN FILM COATED TABLETS 200MG 
學名:HYDROXYCHLOROQUINE SULFATE
含量: 200 (相當於155毫克的基質base)
單位: MG
警語(中文): 視力模糊或任何其他眼毒性偶有暈眩,腸胃不適。如有視力問題,莫名發燒,出血或嚴重腹瀉,請儘速就醫。(另應定期進行視力檢查)
警語(英文): blurred vision or any other ocular toxicity
適應症(中文): 圓盤狀及全身性紅斑性狼瘡、慢性多形日光疹、慢性風濕性關節鹽、鏈狀瘧原蟲和間日瘧原蟲引起之瘧疾。
藥理作用:與瘧疾原蟲的DNA分子產生複合體,而抑制RNA複製,終而抑制核酸的合成,本品的某些衍生物也具有抗阿米巴作用,以及抗發炎和抗組織胺的活性。
懷孕分級:C
[常用劑量]
1. 紅斑狼瘡初始: 400 mg (310 mg base) ORALLY once or twice daily 直到症狀緩解 
2. 紅斑狼瘡維持: 200 to 400 mg (155 to 310 mg base) ORALLY once daily 
3. 瘧疾控制: 400 mg (310 mg base) ORALLY once weekly on the same day; begin 2 weeks prior to entering an endemic area and continue for 8 weeks after leaving the endemic area 
4. 瘧疾負荷劑量 (if unable to start suppressive therapy 2 weeks prior): 800 mg (620 mg base) ORALLY initially, followed by normal suppressive therapy 
5. 瘧疾急性發作期: 800 mg (620 mg base) ORALLY initially, then 400 mg (310 mg base) in 6 to 8 hours and 400 mg once daily for 2 days OR a single dose of 800 mg ORALLY 
6. 類風濕關節炎初始: 400 to 600 mg (310 to 465 mg base) ORALLY once daily for 4 to 12 weeks 
7. 類風濕關節炎維持: 200 to 400 mg (155 to 310 mg base) ORALLY once daily
適應症(英文): Treatment of Malaria, immune modulator 
副作用(中文): 腹瀉、頭痛、皮膚癢、掉髮增加、瘀青、頭暈、皮膚紅疹
副作用(英文): Diarrhea , headache , itching , increasing hair loss , blue-black discoloration of skin fingernails, or oral mucosa , dizziness or lightheadness 
禁忌:網膜受損,視野改變,懷孕,長期用於治療小孩的疾病,接受骨髓抑制劑或溶血性藥物治療的疾病。
注意事項:
1. 下列病人使用本品宜小心:神經性或肝病,葡萄糖6-磷酸去氫酶(glucose-6-phosphated ehydrogenase)缺乏,血液疾病,牛皮癬,嚴重的疾病或酒精中毒。此外,嬰孩和小孩服用本品也要小心。
2. 要知道某些種類的惡性瘧對4-aminoquinolines有抗藥性,需要使用quinine或其他適當的抗瘧藥
3. 告訴病人本品會使尿液呈黃棕色。
4. 暴露在流行病區前至少二個星期就要開始治療,在離開流行病區後至少要連續治療八個星期,每個星期的同一天給藥。
保存方式品應置於攝氏 15 ~ 25 度乾燥處所;如發生變質或過期,不可再食用。
其他用藥指示(中文):
1. 請勿自行停藥
2. 若症狀未見改善,請與醫師連絡
其他用藥指示(英文):
1. Do not stop taking medicine without asking your doctor even you feel better
2. Consult your doctor if symptoms persist within a few days
(廠牌與產地:健亞生物科技 (GENELABS) – TW)

「小檔案」
“健亞”殲瘧膜衣錠200公絲 Geniquin FC Tablet 200mg (Hydroxychloroquine)
功 能:屬於DMARDs類緩效性抗發炎製劑
主要作用
有效治療SLE所有階段的症狀 
降低SLE患者病發的危險性和嚴重性 
超過上億患者服用天數的經驗確認其效用及安全性
提供有效的disease–modifying therapy 
適合RA病患長期治療的使用
對於疼痛的減輕和關節不活動性的降低都優於NSAIDs 
治療毒性比NSAIDs低,已考慮當第一線
作 用:
本品對瘧疾原蟲及腸梨形蟲的作用與瘧靈Aralen phosphate (chloroquine phosphate, USP)類似。
適 應 症:圓盤狀及全身性紅斑性狼瘡、慢性多形日光疹、慢性風濕性關節炎、鐮狀瘧原蟲和間日瘧原蟲引起之瘧疾。
說 明:用於處理焦慮症或暫時舒解之。對帶有抑鬱的焦慮也能生效。
用法用量:
□瘧疾-急性發作的治療: 
成人:初劑量800毫克,然後六至八小時內給予400毫克再繼續服用2天,每天劑量400毫克(總共2克)。 一歲以下的嬰兒:100毫克,然後每六至八小時間隔給藥三次,每次100毫克(總共400毫克)。 二歲至五歲兒童:400毫克,八小時後200毫克(總共600毫克)。 六歲至十歲兒童:400毫克,間隔八小時再服用二次,每次服用200毫克(共800毫克)。 十一歲至十五歲兒童:600毫克,八小時後服用200毫克,二十四小時後再用一克。 
□抑制(Suppression)-成人:每星期同一天服用400毫克。 
□梨形蟲病-成人:每次200毫克,每天三次,服用五天。 
□紅斑性狼瘡和多形性光疹-成人初劑量每天一至二次,每次400毫克,可連續幾星期幾個月。
□長期持續治療則較小劑量即可,即每天200至400毫克。

No comments:

Post a Comment